Discovery Labs developing former GSK facility into $500M healthcare, life sciences tech community

The Discovery Labs, which was formed by MLP Ventures, is developing a $500 million healthcare, life sciences and tech co-working community at the former GlaxoSmithKline facility in King of Prussia, Pennsylvania. (Discovery Labs)

The Discovery Labs, which was formed by MLP Ventures, is developing a $500 million healthcare, life sciences and tech co-working community at the former GlaxoSmithKline facility in King of Prussia, Pennsylvania.

When completed, the campus will feature a 1.6 million-square-foot collaborative laboratory as well as the 640,000-square-foot Innovation at Renaissance Campus. The idea is to turn the site into the world’s largest co-working “ecosystem” for healthcare, life sciences and tech-enabled companies.

GSK continues to operate a sterile injectables manufacturing plant on its East Campus in Upper Merion, Pennsylvania.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“The size of each Discovery Labs enables enterprise level companies to work side by side with startup and emerging companies and enjoy the benefits of the co-working phenomenon,” Audrey Greenberg, Discovery Labs' chief executive, said in a statement. “It is the first of a network of massive co-working properties which will encourage powerful, collaborative innovation on an international scale.”

GSK sold the site last year for a reported $77 million to O’Neill Properties, which later became MLP Ventures.

A major attraction at the campus will be a 100-square-foot incubator operated by the Pennsylvania Biotech Center that will be dubbed IQ Connect. The space will be designed to attract millennial workers by offering on-site coffee shops and restaurants, a $10 million conference center with a 275-seat auditorium and a fitness center that will offer yoga and Pilates classes. They also plan to include walking trails and an outdoor amphitheater.

Suggested Articles

Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.

Turkey is getting its first locally produced mAb via an Iranian biosimilars marker and the $100 million plant it built there.